{"product_id":"revvity-al356c","title":"Revvity, AL356C, AlphaLISA Human PD1 \/ PDL1 Binding Kit, 500 Assay Points","description":"\u003cp\u003eOverview\u003cbr\u003e\nThis kit is designed for the detection of binding activity between PD-1 and PD-L1 using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of therapetics by using competitive binding.\u003cbr\u003e\nFeatures:\u003c\/p\u003e\n\n\u003cp\u003eNo-wash steps, no separation steps\u003cbr\u003e\nEase-of-use: few addition steps, fast assay development\u003cbr\u003e\nBroad range of affinities: detect strong or weak interactions, from pM to mM affinity\u003cbr\u003e\nDistance: measure very large protein or antibody complexes – spanning up to 200 nm or more\u003cbr\u003e\nHigh avidity: multiple binding sites on each bead enables use of nanomolar concentrations of antibodies or proteins, as well as use of low affinity binders\u003c\/p\u003e\n\n\u003cp\u003eAlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated PD-1 binds to the Streptavidin-coated Alpha Donor beads, while His tagged PD-L1 is captured by Anti-His AlphaLISA Acceptor beads. When PD-L1 binding to PD-1 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.\u003cbr\u003e\nProgrammed death ligand 1 (PD-L1), also known as \"cluster of differentiation 274\" (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and is expressed in tumor cells. PD-L1 binds to its receptor, PD-1, found on activated T cells, B cells, and myeloid cells, to modulate activation or inhibition. By binding to PD-1, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression and thus contribute to cancer growth. Monoclonal antibodies targeting PD-1 and PD-L1 are being developed as a means to boost the immune system for the treatment of non-small-cell lung cancer, melanoma, bladder, renal, and triple-negative breast cancers. \u003cbr\u003e\nApplication-Protein-Protein Interaction\u003cbr\u003e\nAutomation Compatible-Yes\u003cbr\u003e\nBrand-AlphaLISA\u003cbr\u003e\nDetection Modality-Alpha\u003cbr\u003e\nProduct Group-Kit\u003cbr\u003e\nSample Volume-10 µL\u003cbr\u003e\nShipping Conditions-Shipped in Blue Ice\u003cbr\u003e\nTarget-PD-1~PD-L1\u003cbr\u003e\nTarget Class-Binding Assay\u003cbr\u003e\nTarget Species-Human\u003cbr\u003e\nTechnology-Alpha\u003cbr\u003e\nTherapeutic Area-Immuno-oncology\u003cbr\u003e\nUnit Size-500 assay points\u003c\/p\u003e","brand":"Revvity","offers":[{"title":"Default Title","offer_id":46774559604905,"sku":"AL356C","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/revvity-al356c","provider":"Iright","version":"1.0","type":"link"}